# ApoE testing

Source: https://onco.cc/technologies/da-tech-apoe-testing/  
OnCo record `da-tech-apoe-testing` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ApoE ε4 is a risk variant used in antibody-safety counselling. It does not diagnose Alzheimer’s disease.

## Summary

US labels for amyloid antibodies discuss ApoE ε4 and ARIA risk. Testing needs consent and counselling, not a casual consumer kit used as a diagnosis.

## Fields

- Kind: Technology
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Principle: Genotyping APOE alleles, especially ε4, to inform ARIA risk discussions.

## Sources

- FDA Leqembi: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- fronts: [Genetics](https://onco.cc/fronts/da-front-genetics/)
- drugs: [Donanemab](https://onco.cc/drugs/da-donanemab/), [Lecanemab](https://onco.cc/drugs/da-lecanemab/)

---
JSON: https://onco.cc/api/v1/entities/da-tech-apoe-testing.json